FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 169 filers reported holding FATE THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 9.78 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $8,020 | +143.8% | 1,407 | +331.6% | 0.00% | – |
| Q4 2022 | $3,289 | -34.2% | 326 | +57.5% | 0.00% | -100.0% |
| Q3 2022 | $5,000 | -16.7% | 207 | -11.9% | 0.00% | 0.0% |
| Q2 2022 | $6,000 | -14.3% | 235 | +23.7% | 0.00% | 0.0% |
| Q1 2022 | $7,000 | -78.8% | 190 | -65.8% | 0.00% | -80.0% |
| Q4 2021 | $33,000 | +1550.0% | 556 | +1444.4% | 0.01% | +400.0% |
| Q3 2021 | $2,000 | -33.3% | 36 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $3,000 | -50.0% | 36 | -47.8% | 0.00% | 0.0% |
| Q1 2021 | $6,000 | +100.0% | 69 | +91.7% | 0.00% | 0.0% |
| Q4 2020 | $3,000 | – | 36 | +200.0% | 0.00% | – |
| Q3 2020 | $0 | -100.0% | 12 | -97.7% | 0.00% | -100.0% |
| Q2 2020 | $18,000 | +1700.0% | 512 | +1090.7% | 0.01% | – |
| Q1 2020 | $1,000 | -97.4% | 43 | -97.8% | 0.00% | -100.0% |
| Q4 2019 | $39,000 | – | 2,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $7,163,616 | 2.64% |
| Redmile Group, LLC | 13,124,427 | $27,823,785 | 1.32% |
| Monaco Asset Management SAM | 1,847,944 | $3,917,641 | 1.16% |
| Casdin Capital, LLC | 2,050,000 | $4,346,000 | 0.48% |
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $1,484,000 | 0.21% |
| GCM Grosvenor Holdings, LLC | 495,916 | $1,051,342 | 0.21% |
| Nebula Research & Development LLC | 163,617 | $346,868 | 0.18% |
| Bellevue Group AG | 4,851,579 | $10,285,347 | 0.17% |
| Bruce & Co., Inc. | 200,000 | $424,000 | 0.14% |
| XTX Topco Ltd | 192,920 | $408,990 | 0.07% |